MARKET

BIO

BIO

Bio Rad
NYSE

Real-time Quotes | Nasdaq Last Sale

567.92
+5.92
+1.05%
After Hours: 567.92 0 0.00% 16:42 03/05 EST
OPEN
566.41
PREV CLOSE
562.00
HIGH
571.43
LOW
552.86
VOLUME
208.63K
TURNOVER
--
52 WEEK HIGH
689.00
52 WEEK LOW
309.38
MARKET CAP
16.95B
P/E (TTM)
4.498
1D
5D
1M
3M
1Y
5Y
Bio-Rad to Participate in Barclays Global Healthcare Conference 2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive V...
Business Wire · 1d ago
Fitch Rates Agilent's Senior Unsecured Notes 'BBB+'
reuters.com · 4d ago
Bio-Rad Laboratories (BIO) Initiated with a Buy at Oppenheimer
Oppenheimer analyst Kevin DeGeeter initiated coverage with a Buy rating on Bio-Rad Laboratories (BIO) yesterday and set a price target of EUR2.00. The
SmarterAnalyst · 5d ago
Fitch Upgrades Thermo Fisher's Long-Term IDR to 'BBB+'; Outlook Stable
reuters.com · 5d ago
Top Stocks for March 2021
These are the stocks with the best value, fastest growth, and most momentum for March.
Investopedia · 02/24 19:25
Flow Cytometry Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2025
Feb 23, 2021 (Heraldkeepers) -- Flow cytometry is a bio-physical, laser-based logical generation that measures and analyzes numerous physical characteristics...
Heraldkeepers · 02/23 13:34
What Makes Bio-Rad Laboratories (BIO) a Strong Momentum Stock: Buy Now?
Zacks.com · 02/22 21:59
Bio-Rad to Participate in Citis 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
Business Wire · 02/22 21:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIO. Analyze the recent business situations of Bio Rad through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIO stock price target is 752.50 with a high estimate of 775.00 and a low estimate of 725.00.
EPS
Institutional Holdings
Institutions: 695
Institutional Holdings: 21.00M
% Owned: 70.37%
Shares Outstanding: 29.84M
TypeInstitutionsShares
Increased
175
1.86M
New
122
-56.81K
Decreased
169
1.19M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.73%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Chairman/President/Chief Executive Officer/Director
Norman Schwartz
Chief Financial Officer/Executive Vice President
Ilan Daskal
Chief Operating Officer/Executive Vice President
Andrew Last
Executive Vice President/General Counsel/Secretary
Timothy Ernst
Executive Vice President
Michael Crowley
Executive Vice President
Giovanni Magni
Executive Vice President
Annette Tumolo
Executive Vice President
Dara Wright
Senior Vice President/Chief Accounting Officer
Ajit Ramalingam
Vice President/Treasurer
Ronald Hutton
Lead Director/Independent Director
Gregory Hinckley
Director
Alice Schwartz
Independent Director
Jeffrey Edwards
Independent Director
Melinda Litherland
Independent Director
Arnold Pinkston
No Data
  • All
  • Financials
  • Insiders
More
About BIO
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Webull offers kinds of Bio-Rad Laboratories, Inc. stock information, including NYSE:BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.